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Abstract
Neuronal nicotinic acetylcholine receptors (nAChRs) of the cholinergic system have been
linked to antinociception, and therefore could be an alternative target for pain alleviation.
nAChR activity has been shown to be regulated by the nicotinic modulator, lynx1, which
forms stable complexes with nAChRs and has a negative allosteric action on their function.
The objective in this study was to investigate the contribution of lynx1 to nicotine-mediated
antinociception. Lynx1 contribution was investigated by mRNA expression analysis and
electrophysiological responses to nicotine in the dorsal raphe nucleus (DRN), a part of the
pain signaling pathway. In vivo antinociception was investigated in a test of nociception, the
hot-plate analgesia assay with behavioral pharmacology. Lynx1/α4β2 nAChR interactions
were investigated using molecular dynamics computational modeling. Nicotine evoked
responses in serotonergic and GABAergic neurons in the DRN are augmented in slices
lacking lynx1 (lynx1KO). The antinociceptive effect of nicotine and epibatidine is enhanced
in lynx1KO mice and blocked by mecamylamine and DHβE. Computer simulations predict
preferential binding affinity of lynx1 to the α:α interface that exists in the stoichiometry of the
low sensitivity (α4)3(β2)2 nAChRs. Taken together, these data point to a role of lynx1 in
mediating pain signaling in the DRN through preferential affinity to the low sensitivity α4β2
nAChRs. This study suggests that lynx1 is a possible alternative avenue for nociceptive
modulation outside of opioid-based strategies.
Introduction
Pain is amongst the most common reasons for seeking medical treatment, however approxi-
mately 80 percent of pain sufferers worldwide do not have sufficient access to proper care [1–
2]. The most widely used therapies for acute nociceptive pain involve agonists of the opioid
receptors. Such agents, however, carry risk for major off-target effects [3], along with the high
propensity for overdose, abuse and the development of tolerance [4], which is a rapidly
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growing medical and societal concern in the US [5]. Analgesia can be achieved by influencing
pathways other than the opioidergic pathways [6] and one promising alternate avenue outside
of opioid agents is to exploit the antinociceptive effects of the cholinergic system, more specifi-
cally neuronal nicotinic acetylcholine receptors (nAChRs) of this neurotransmitter system.
Stimulation of nAChRs have been shown to produce antinociception by several pharmaco-
logical studies [7–12]. nAChRs are activated by the endogenous neurotransmitter acetylcho-
line and the exogenous drug nicotine [13]. Neuronal nAChRs exist in combinations of either
heteropentameric or homopentameric complexes of α2-10and β2–4 nAChR subunits and the
majority of nAChRs in the brain consist of α4β2 heteropentamers or α7 homopentamers [14–
17].The subunit composition and stoichiometry of nAChRs affect the response profile of the
receptor [18] and studies on acute pain have shown that specifically, α4β2 [7–12] α5 [19], α6-
containing [20], α7 [21–23] and α9-containing [24] nAChR subtypes are important compo-
nents in the nAChR-mediated antinociception pathway [25].
Pain signaling emanates from the periphery and involves the spinal cord [26], periaque-
ductal gray and dorsal raphe nucleus (DRN) etc. [27]. nAChRs can directly modulate sero-
tonergic neurons in the DRN to influence nociception, resulting in antinociceptive activity
[28–30]. Extracellular nicotine has been shown to elicit an increase in the firing rate of most
DRN neurons, thus enhancing serotonin release causing antinociception [29–30]. Another
region of interest in the pain signaling is the dorsal horn of the spinal cord, which also
expresses nAChRs. Spinal nAChRs have been shown to have both nociceptive and antinoci-
ceptive roles [31]. Endogenous acetylcholine in the spinal cord tonically drives baseline sig-
naling, which can alter the thresholds for pain [32]. The periaqueductal gray is a relay
station between brain regions such as the hypothalamus and the spinal cord that contains
α7 nAChRs, and when locally activated, these α7 receptors can cause antinociception [33].
Peripheral nAChRs in the dorsal root ganglion neurons also carries nociceptive and antino-
ciceptive sensory signaling [34–35]. The use of α4β2 and α7 nAChR agonists in this area
induce antinociception [36–38]. Thus, modulation of nAChRs expressed in these pathways
can contribute to antinociception.
Protein modulators of nAChRs represent an avenue of investigation into the role of
nAChRs in antinociception. Lynx genes belong to the Ly-6/uPAR superfamily [39] which
are evolutionarily related to genes coding for snake venom toxins. Like snake venom toxins
and other prototoxins [40–43], the lynx1 protein binds to nAChRs and modulates their
function [44]. Both snake venom toxins and lynx1 proteins have a three-looped binding fold
which is an efficient receptor binding scaffold [45–46]. Lynx1 has been shown to form stable
complexes with both α4β2 and α7 nAChR subunits on CNS neurons [44] and through its
binding to nAChRs, as early as in the endoplasmatic reticulum [47], it can have overall com-
plex effects on nicotinic receptor function; lynx1 binding results in reduced agonist sensitiv-
ity, increased desensitization rate, and slower recovery from desensitization of nAChRs
[48], and increase in the mean closed time measured at the single-channel level [49]. The
biophysical mechanism of action of lynx1 on nAChR function, and the widespread expres-
sion of nAChRs, suggest a complex, multimodal role of lynx1 on nAChR-dependent pro-
cesses. The functional in vivo consequences have been tested in lynx1 knockout (KO) mice,
and thus far, increased associate learning, improved memory [48] and extended critical
period of plasticity in the visual system [50], have been reported. Although this establishes
the functional significance of these modulatory proteins, other nicotinic-dependent pro-
cesses such as antinociception have yet to be investigated. With the detection of lynx1
expression in brain regions linked to nociception processing reported herein, we sought to
assess nAChR-mediated antinociception.
Lynx1 antinociception modulation
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Materials and methods
Model organism
Genetically modified female and male mice were used as the model organism for this study.
Both wild type (wt) (C57BL/6J), lynx1KO and β2-GFP knockin mice were used. The mice
tested were between the ages of 3–7 months (20-50g) for the nicotine-, epibatidine- and dihy-
dro-β-erythroidine hydrobromide (DHβE) assays and 6–8 months (30-50g) for the mecamyl-
amine (mec)-, locomotion- and temperature assays. Naïve mice were used for the nicotine-,
epibatidine- and DHβE assays, and reused for the mec-, locomotion- and temperature assays
with sufficient time in between assays (minimum 1 week). Adult naïve mice were used for
PCR, immunohistochemical staining and western blot analysis. For the electrophysiological
experiment 16–18 days old naïve mice were used. The lynx1KO and β2-GFP mice were trans-
ferred from the California Institute of Technology in Pasadena, CA, USA or bred at Lehigh
University, PA, USA. Lynx1KO mice were generated using 129 ES cells [48] and backcrossed
over 12 generations to the C57BL/6J background. β2-GFP knock-in mice were generated in
the Lester laboratory, California Institute of Technology in Pasadena, CA, USA, and trans-
ferred to the Lehigh Central Animal Facility. Mice were kept on a 12:12 light-dark cycle and
food and water were provided ad libitum. The mice were kept with up to 4 other mice and
were ear punched for identification purposes. All procedures and protocols were approved
and in compliance with Lehigh IACUC guidelines on the humane care and use of animals
(IACUC protocol #147). All efforts were made to minimize animal suffering. Animal studies
are reported in compliance with ARRIVE guidelines.
Genotyping
All mice were genotyped using a polymerase chain reaction assay. A mouse tail biopsy was
obtained before and after experimentation for both pre- and post-hoc genotyping. The DNA
was lysed overnight with Proteinase K and extracted using isopropanol or Qiagen© DNA
Miniprep Kit (Qiagen, Hilden, Germany). The DNA was amplified through a standard poly-
merase chain reaction protocol. Each tissue sample was genotyped 2–3 times before a confir-
mation of the genotype was assigned.
Quantitative PCR and RT-PCR
Tissue from the DRN was dissected and RNA was extracted using the RNeasy Mini kit (Qia-
gen, Hilden, Germany). Purified RNA was synthesized into cDNA using the qScript cDNA
SuperMix (Quanta Bioscience, Beverly, MA, USA). Quantitative PCR was performed in tripli-
cate using lynx1 TaqMan gene expression assay (ThermoFisher Scientific, Waltham, MA,
USA) with GAPDH as reference gene. The expression of target genes was normalized to the
expression of the reference gene [51]. PCR products were run on a 4% agarose gel. Further-
more, RT-PCR was also carried out using tryptophan hydroxylase 2 primers (FW: 5’CTGA
AAGAGCGATCTGGCTTC3’, Rev: 5’ATCTGGTTCCGGGGTGTAGA3’) (Integrated DNA tech-
nologies, USA) to confirm localization of RNA to the DRN. PCR products were run on a 2%
agarose gel.
Lynx1 immunohistochemical staining
Adult β2-GFP knockin mice were anesthetized and perfused with saline followed by 4% para-
formaldehyde/PBS (pH 7.4) followed by rapid decapitation. Perfused brains were dissected,
and post-fixed in 4% paraformaldehyde/PBS for 3 hours followed by 30% sucrose/PBS. Dis-
sected brains were sectioned at 50 μm on a freezing microtome. Experiments were done by
Lynx1 antinociception modulation
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incubating free-floating sections. Sections were stained with custom made anti-lynx1 mono-
clonal antibodies (1:1000, 1.7 ng/μl)[44]) o/n, and incubated with Alexa Fluor 568 conjugated
anti-mouse secondary antibodies at 1:1000 dilution for 1 hour at RT (ThermoFisher Scientific,
Waltham, MA, USA). Serotonergic neurons were identified using an anti-TPH2 (Tryptophan
hydroxylase 2) antibody (1:500, ThermoFisher Scientific, Waltham, MA, USA) o/n, and incu-
bated with Cy-2 conjugated donkey anti-rabbit secondary antibodies at 1:2000 dilution (Jack-
son Immunochemicals, West Grove, PA, USA) at RT for 1 hour. Sections were also incubated
with rabbit polyclonal antibodies against lynx1 ([39]. These antibodies were custom generated
against a synthetic lynx1 peptide (TTRTYFTPYRMKVRKS) and previously tested by immuno-
fluorescence and immunocytochemistry staining at 1:2000 dilution [39]. To confirm the speci-
ficity of staining of this antisera, affinity-purified anti-lynx1 antibodies were tested by Western
blot of mouse brain extracts to confirm ~9–12 kD band size, using antibodies purified on a
nickel column to purify a bacterially produced lynx1-his protein, and subsequently tested on
Western blots from lynx1KO mouse brain extracts. The staining in the lynx1 +/+ mouse brains
demonstrated band at the expected band size, and no band was present in the lynx1KO -/-
brain samples [48]. DRN sections were incubated with anti-lynx1 antisera at 1:1000 dilution
for 1 hour at RT. After washing, sections were incubated with Cy-2-conjugated donkey anti
rabbit at 1:200 (Jackson Immunoresearch, West Grove, PA, USA) for 1 hour at RT. Sections
were mounted on microscope slides and imaged using Nikon elements software on Nikon
E1000 confocal microscope.
Dual labeling immunofluorescence
Adult C57bl6 mice were perfused as described above. Dissected brains were sectioned at 50μm
on a freezing microtome. Serotonergic neurons were identified using an anti-TPH2 (Trypto-
phan hydroxylase 2) antibody (1:500, ThermoFisher Scientific, Waltham, MA, USA) o/n, and
incubated with Cy-2 conjugated donkey anti-rabbit secondary antibodies at 1:2000 dilution
(Jackson Immunochemicals, West Grove, PA, USA) at RT for 1 hour. Sections were co-stained
with custom made anti-lynx1 monoclonal antibodies raised against mouse lynx1 protein puri-
fied from bacteria and refolded (Green Mountain Laboratories, mouse, 1:1000, 1.7 ngμl-1)
[44] o/n, and incubated with Alexa Fluor 568 conjugated anti-mouse secondary antibodies at
1:1000 dilution for 1 hour at RT (ThermoFisher Scientific, Waltham, MA, USA). Sections
were mounted and imaged using Nikon elements software on Nikon E1000 confocal micro-
scope at 10, 20, 40 and 100x magnification. Sections were also stained singly with either anti-
TPH2 or anti-lynx1 antibodies to establish staining pattern and control for bleed through
staining. To further confirm the specificity of lynx1 staining, we stained side by side DRN sec-
tions with anti-lynx1 polyclonal and anti-TPH2 antibodies.
Co-immunoprecipitation (Co-IP)
β2-GFP knockin dorsal brain regions containing the DRN were dissected and immediately
homogenized in the bullet blender tissue homogenizer (NextAdvance, Averill Park, NY, USA),
with Co-IP buffer (50 mM Tris, 150 mM NaCl, 0.75% Triton-X 100, Pierce protease inhibitor
cocktail). Dynabeads A (ThermoFisher Scientific, Waltham, MA, USA) were pre-incubated
with 10μg rabbit anti-GFP primary antibodies (ThermoFisher Scientific,Waltham, MA, USA)
and thoroughly washed. Brain homogenates at a concentration of 13 mgml-1 were incubated
with the dynabeads-antibody complex for 3 days rotating at RT. After washing, GFP fusion
protein complexes including interacting proteins were eluted and immediately prepared for
western blot analysis.
Lynx1 antinociception modulation
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Electrophysiology
Animals, aged 16–18 days, were split into 2 groups according to their genotype. The mice were
deeply anaesthetized with isoflurane. Frontal midbrain slices at 300 μm were made with a
Vibratome (Vibratome Co., St Louis, MO, USA), and the slices were incubated in an oxygen-
ated sucrose solution at 35˚C for 1 hour. The recordings were perfused with Ringer solution
containing the following ingredients (in mM): NaCl 128, KCl 2.5, NaH2PO4 1.25, CaCl2 2,
MgSO4 1, NaHCO3 26, and dextrose 10, pH 7.4. Whole-cell patch clamp recordings were con-
ducted in DRN slices visualized through an upright microscope (Scientifica, UK) equipped
with infrared differential interference contrast optics (IR-DIC). Resistance of the recording
pipette (1.2 mm borosilicate glass) was 7–9 MO. Tips of the recording pipettes were filled with
a potassium gluconate-based intracellular solution: potassium gluconate 120, KCl 6, ATP-Mg
4, Na2GTP 0.3, EGTA 0.1, and Hepes 10, pH 7.3, 310 mosmolL-1. Cell type identification
using the action potential (AP) shoulder was performed under current clamp recording condi-
tions to discriminate serotonergic neurons (with shoulder) and GABAergic neurons (without
a shoulder). The cell was then switched into voltage clamp mode and held at -70 mV for the
assessment of nicotine-evoked peak responses. Nicotine was dissolved in ACSF for fast-appli-
cation to the neuronal cell body using a Picospritzer (20 p.s.i., 200 ms) to pressure-eject the
nicotine solution (Parker Hannifin corporation). The peak value of response was measured
and statistically analyzed among different groups.
Western blot analyses
Samples were denatured in 1x sample buffer (ThermoFisher Scientific, Waltham, MA, USA) at
95˚C and run on a 15% SDS-PAGE gel. Gels were transferred onto activated PVDF membrane
via semi-dry transfer. The membrane was blocked with 5% milk/0.05% Tween-PBS for 1 hour
at 4˚C followed by an overnight incubation at 4˚C in T-15 anti-lynx1 (1:1000, Santa Cruz Bio-
technology, Dallas, TX, USA). After thorough washing, the membrane was incubated with
conjugated donkey anti-goat (Abcam, Cambridge, MA, USA) at 1:10,000 for 1 hour at 4˚C.
Membranes were incubated in ECL (ThermoFisher Scientific,Waltham, MA, USA) and
exposed to film. Actin controls were run using mouse anti-actin (Abcam, Cambridge, MA,
USA) at 1:1000 dilution, and goat anti-mouse (Life Technologies, Carlsbad, CA, USA) at
1:40,000 dilution.
Drugs
Nicotine hydrogen tartrate salt (free base nicotine concentrations of 0.25−1.5 mgkg-1) (Sigma-
Aldrich, St. Louis, MO, USA), mec (2.5 mgkg-1) (Abcam, Cambridge, MA, USA), DHβE (3.0
mgkg-1) (Tocris Bioscience, Bristol, UK), epibatidine (5 μgkg-1) (Tocris Bioscience, Bristol,
UK), and Ibuprofen sodium (20 mgkg-1) (Sigma-Aldrich, St. Louis, MO, USA) were dissolved
in 0.9% saline. The volume of liquid injected into the mice was calculated based on animal
weight of ~10 mlkg-1 [52]. The control animals were injected with 0.9% saline.
Hot-plate assay
The hot-plate test was used to measure response latencies according to a method previously
described [53]. The hot-plate (Columbus Instruments, Columbus, OH, USA) was set at a tem-
perature of 55˚C, and the latency to lick the hind-paw or jump off the surface was evaluated as
an index of nociception. Immediate signs of temperature sensation such as fluttering of the
feet or licking of the front paws were also noted, however the mice were not removed from the
hot-plate until jumping or hind-paw licking. A cutoff time of 60 seconds was determined [11].
Lynx1 antinociception modulation
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Mice were examined and no tissue damage post experiment was observed. If a mouse reached
60 seconds on the hot-plate without demonstrating one of our two proposed nociceptive indi-
cators, the mouse was removed from the hot-plate and a time of 60 seconds was recorded.
Mice were injected with either saline (n = 8, 8; wt, lynx1KO, respectively), free base nicotine
concentrations of 0.25 mgkg-1 (n = 8, 8) 0.5 mgkg-1 (n = 8, 9), 1.0mgkg-1 (n = 8, 14) and
1.5mgkg-1 (n = 8, 8) epibatidine, 5 μgkg-1 (n = 16, 13), or ibuprofen 20 mgkg-1 [54] (n = 10,
12)15 minutes prior to testing on the hot-plate. For the nAChR blocker mecamylamine (mec),
mice were given an injection of 2.5 mgkg-1 (n = 16, 13) 15 minutes prior to hot-plate testing.
Ten minutes after mec injection the mice were injected with nicotine (1 mgkg-1). The β2-spe-
cific nAChRs inhibitor dihydro-β-erythroidine hydrobromide (DHβE) were injected IP at a
dose of 3.0 mgkg-1 (n = 6, 6) 25 minutes prior to hot-plate testing. Ten minutes after DHβE
injection mice were injected with nicotine (0.5 mgkg-1). Animals were split into groups
according to their genotype and randomized with respect to males and females.
Locomotion Assay: Wt and lynx1KO mice were injected with the same free base nicotine
concentrations as in the hot-plate test (saline n = 5,6; wt, lynx1KO, respectively, 0.5 mgkg-1
n = 7, 8, 1.0 mgkg-1 n = 6, 6 and 1.5 mgkg-1 n = 6, 6). Motor activity was assessed by videotap-
ing and measuring the amount of leg movements in seconds in the time period 15–20 minutes
post injections. In addition, leg movements in the time period 5–10, 10–15, and 15–20 minutes
post injection for saline (n = 5 wt, 6 L1KO) and 0.5 mgkg-1 (n = 3 wt, 3 L1KO) to confirm that
no difference in locomotor activity between genotypes was observed at any relevant time
period.
Body temperature assay
Wt and lynx1KO mice were injected with either saline (n = 8, 11; wt, lynx1KO, respectively) or
free base nicotine (1.0 mgkg-1 n = 8, 11, and 2.5 mgkg-1 n = 7, 7). 15 minutes before and after
injections temperature was measured in degrees Celsius (˚C) using a 20 mm rectal probe for
mice (BrainTree Scientific Inc., Braintree, MA, USA).
Computer modeling of lynx1-AChR complexes
A low-resolution structure model of α4:α4/lynx1 complex was first generated using a tem-
plate-based approach. The structure of α4 subunit and that of lynx1 were taken from the Pro-
tein Data Bank (PDB) entries 5kxi [55] and 2l03 [45], respectively. Each target structure (α4
subunit or lynx1) was searched against all known proteins in the PDB to identify the PDB pro-
teins (templates) having similar global structures. The global structure similarity between the
target and template structures was measured by TM-align [56]. The PDB protein searches
identified a PDB entry, 4hqp (α7 nicotinic receptor chimera in complex with α-bungarotoxin,
Figure A in S1 Fig) containing templates for both targets in the single PDB entry. A α4:α4/
lynx1 complex model (Figure B in S1 Fig) was built by mapping the α4 subunit and lynx1 onto
α7 subunits and α-bungarotoxin, respectively.
The α4 subunit structure has a closed-in conformation of loop C. In addition, the structure
of lynx1 has more structured loop I, compared to other members of lynx family (e.g., CD59,
candoxin, erabutoxin-a) [45]. These structural features result in a number of bad contacts in
the initial low-resolution α4:α4/lynx1 complex model. The model was refined through mini-
mizing the bad contacts. We sampled thermally acceptable 100 conformations for α4 loop C
and lynx1 loop I using Backrup application in Rosetta [57], generating 100 × 100 combinations
of α4:α4/lynx1 complexes with different loop conformations. For each complex, lynx1 was
moved outwards from α4:α4 by 2 Å using an interval of 1 Å along a vector defining the geo-
metric centers of two protein binding surfaces to find a complex structure with the minimum
Lynx1 antinociception modulation
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number of bad contacts. The refined α4:α4/lynx1 complex model was subjected to 150-ns
molecular dynamics (MD) simulations to obtain a high-resolution complex model. During the
simulations, weak positional restraints were applied to the backbone heavy atoms of α4:α4,
aiming at maintaining the pentameric orientation of α4:α4. For lynx1, we applied or removed
the positional restraints every 10-ns to prevent dissociation of lynx1 from α4:α4. No restraints
were applied to loop B, loop C, and β8-β9 loop in α4:α4 and loop I in lynx1, allowing their con-
formational flexibility, as they might involve protein-protein interactions. After the 150-ns
simulations, we removed all the positional restraints to lynx1 and performed additional 100-ns
simulations for equilibration. All MD simulations were prepared through CHARMM-GUI
[58–59] and performed with explicit water molecules and 150 mM KCl for physiological salt
concentration using CHARMM36 force filed [60] and NAMD software [61] at 303.15 K. The
final snapshot was energy-minimized and used to describe atomic level interactions between
α4:α4 and lynx1 in the complex model.
To generate a β2:β2/lynx1 complex model, we used the same template-based modeling
approach based on PDB: 4hqp and simulation protocol as α4:α4/lynx1. In the case of β2:β2/
lynx1, however, we did not perform the additional 100-ns equilibration MD simulations. For a
structure comparison of α4:α4/lynx1 with β2:β2/lynx1, lynx1 structure in the final α4:α4/lynx1
complex model was copied onto β2:β2 to generate the β2:β2/lynx1 complex model.
Data presentation and statistical analyses
Hot-plate, locomotion and body temperature data were presented as mean ±S.E.M. Data were
analyzed using either the Student T-test or the two-way ANOVA test with a Tukey post-hoc
test. All assumptions for the Student’s T-test and two-way ANOVA were considered. A p-
value less than 0.05 was considered statistically significant. All statistical tests were performed
in IBM SPSS Statistics 24 (IBM Corporation, Armonk, NY, USA). The data and statistical anal-
ysis comply with the recommendations on experimental design and analysis in pharmacology.
Results
We chose the DRN to begin our investigations because it has been shown to mediate nocicep-
tive signals and express high levels of nAChRs which when activated contribute to antinocicep-
tion [10]. To determine whether the DRN express lynx1, the mRNA expression of lynx1 and
TPH2 in the DRN was analysed using quantitative PCR (relative expression lynx1/GAPDH:
0.0024) and Reverse Transcriptase PCR (RT-PCR) (Fig 1A). We chose TPH2 as a marker of
the DRN, since it is an enzyme involved in the synthesis of serotonin, and is highly enriched in
the DRN [62–63]. Although this establishes the expression of lynx1 in the DRN, we sought an
independent confirmation using another methodology. We also performed immunohisto-
chemical staining using previously published anti-lynx1 antibodies. Immunofluorescence
staining using a polyclonal antibody specifically shown to label lynx1 protein [39, 48, 50],
showed expression of lynx1 in ventral regions of the DRN as compared to dorsal regions of the
DRN (Fig 1B and 1C) or outside the DRN (Figure C in S1 Fig). Side by side comparative stain-
ing of anti-lynx1 monoclonal [44], and anti-TPH2 polyclonal antibody (Fig 1D and 1E),
showed similar regions of staining of TPH2 and lynx1 in the region of the DRN. Co-labeling
studies with these same antibodies showed areas of dual labeling of lynx1 and TPH2, as well as
lynx1 staining which were not labeled with TPH2 at 10x (Fig 1F), 20x (Fig 1G), and 40x (Fig
1H) magnification. This indicates that lynx1 is expressed in both serotonergic and non-seroto-
nergic neurons in the DRN.
We next were interested to understand if lynx1 modulates nAChRs in the DRN, using
lynx1KO slices to assess nicotine-evoked response properties (Fig 2A). There are two major
Lynx1 antinociception modulation
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Fig 1. Establishing lynx1 expression in brain regions associated with nociception. (A) Evidence of lynx1 mRNA expression in
the dorsal raphe nucleus via RT-PCR using lynx1-specific primers (expected band size of 62 bp). Expression of TPH2 (expected
band size of 147 bp) validates that the isolation is in the correct region of interest. (B) Schematic of the brainstem at the level of
Lynx1 antinociception modulation
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cell types in the DRN, serotonergic and GABAergic, which can be discriminated by the action
potential shape [65], with the serotonergic neuron having a shoulder in the falling phase of the
the DRN, as a coronal plane of section (C) Expression of lynx1 protein (green) in the dorsal raphe nucleus, using anti-lynx1 pAb
immunofluorescence staining [39, 64]and donkey anti-rabbit Cy2 secondary antibody, imaged at 4x magnification. (D and E)
Side by side labeling of lynx1 (anti-lynx1 mAb, Alexa red), and TPH2 (anti-TPH2 pAb, Cy2, green), 10x magnification, scale
bar = 200 μm. (F) Dual labeling immunofluorescence staining using anti-lynx1 mAb (red) and anti-TPH2 pAb (green), merge
(yellow), 20x magnification, scale bar = 100 μm. (G) Dual labeling immunofluorescence staining using anti-lynx1 mAb (red)
and anti-TPH2 pAb (green), merge (yellow), 40x magnification, scale bar = 50 μm.
https://doi.org/10.1371/journal.pone.0199643.g001
Fig 2. Modulatory effect of lynx1 on nicotine responses in the dorsal raphe nucleus. (A) Photomicrograph of a live brain slice containing the dorsal
raphe nucleus (B) Representative trace of an action potential from a GABAergic-like (without AP shoulder, left) and serotonergic-like neuron (with
AP shoulder, right) recorded in current-clamp mode. Left upper panel is a single action potential at a faster time scale and lower panel is a spike train
at high frequency of the GABAergic neuron. Right upper panel is a single AP at a faster time scale, and lower panel is a spike train at low frequency of
the serotonergic neuron. Arrow points to the AP shoulder which is a hallmark of serotonergic neurons. (C) Representative original traces and average
nicotine-evoked current amplitude of neuronal cell bodies recorded in voltage-clamp mode held at -70mV. Nicotine induced stronger responses both
in GABAergic and serotonergic neurons of Lynx1 KO (white) neurons than wild-type (black) in dorsal raphe nucleus (GABAergic neurons: wt
47.8 ± 16.1 pA, n = 9 (mice N = 3) vs. lynx1KO 170 ± 38.2 pA, n = 17 (mice N = 6); p = 0.008, student t test. Serotonergic neurons: wt 61.0 ± 13.2 pA,
n = 12 (mice N = 4) vs. lynx1KO 164 ± 34.6 pA, n = 19 (mice N = 6); p = 0.01, student t test).
https://doi.org/10.1371/journal.pone.0199643.g002
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action potential. We obtained whole-cell measurements from these two neuronal cell types in
the DRN, the neurons with an AP shoulder being serotonergic-like neurons (serotonergic)
and those without an AP shoulder being GABAergic-like (GABAergic) neurons, using these
parameters to discriminate them from one another (Fig 2B) [65]. We measured acute
responses to fast application of pressure-ejected nicotine (200 μM) in neurons of brain slices in
the DRN from wt and lynx1KO. We found that there were differences in the peak response
between wt and lynx1KO neurons (Fig 2C), with higher peak nicotine response in neurons
from lynx1KO vs wt slices (GABAergic neurons: wt 47.8 ± 16.1 pA, n = 9 (mice N = 3) vs.
lynx1KO 170 ± 38.2 pA, n = 17 (mice N = 6); p = 0.008, student t test. Serotonergic neurons:
wt 61.0 ± 13.2 pA, n = 12 (mice N = 4) vs. lynx1KO 164 ± 34.6 pA, n = 19 (mice N = 6);
p = 0.01, student t test), in response to fast application of nicotine between the two genotypes
and in both cell types (Fig 2C). These data demonstrate a modulatory action of lynx1 on nico-
tinic receptors in one of the brain regions involved in nociceptive signaling.
To address this possibility, we sought to understand the effect of lynx1 in our genetic mice
using a behavioral test of acute thermal nociception. Lynx1KO mice have been shown to be
more sensitive to the effects of nicotine in electrophysiological, motor learning assays [48] and
visual evoked responses in the visual cortex [50] and therefore we predicted that the lynx1KO
mice would be augmented in either baseline nociceptive responses and/or sensitivity to the
antinociceptive effects of nicotine. We conducted thermal assays in wt and lynx1KO mice
using a hot-plate paradigm. The sensitivity to the heat from the hot-plate was assessed by mea-
suring the response latency to react (secs) under saline and nicotine conditions. No differences
in baseline (saline) nociception between wt and lynx1KO mice were found (mean difference
0.8 sec, p = 0.899, two-way ANOVA. n = 8, 8; wt, lynx1KO, respectively. Cohen’s D 0.13). Both
genotypes, however, showed a dose-dependent increase in time spent on the hot-plate after
nicotine administration (Fig 3A, Figure A in S2 Fig). Lynx1KO mice showed more sensitivity
to nicotine as compared to wt mice at lower doses (0.5 mgkg-1 nicotine; mean difference 13.4
sec, p = 0.034, two-way ANOVA, n = 8, 9, Cohen’s D 1.37. 1.0 mgkg-1 nicotine; mean differ-
ence 12.2 sec, p = 0.034, two-way ANOVA, n = 8, 14, Cohen’s D 1.09). These data suggest that
genetic removal of lynx1 in mice increased the antinociceptive actions of nicotine. We saw no
differences due to sex (Fig 3B).
Next, we blocked nAChRs using a non-selective channel blocker of nAChRs, mecamyl-
amine, in the same hot-plate assay. We injected nicotine (1 mgkg-1) 10 minutes after meca-
mylamine (2.5 mgkg-1) injection. We found that blocking nAChRs with mecamylamine was
able to inhibit the augmentation in nicotine-mediated antinociception observed in both wt
and lynx1KO mice (Fig 3C) to normal levels of responsiveness similar to saline injected con-
trols (nicotine-treated lynx1KO vs. nicotine+mec treated lynx1KO mice: mean difference 21.1
sec, p = 0.0001, Student’s T-test, nicotine-treated lynx1KO vs. mec treated lynx1KO mice:
mean difference 26.15 sec, p<0.00001, Student’s T-test, nicotine-treated wt vs. nicotine+mec
treated wt mice, mean difference 15.4 sec, p = 0.002, saline treated wt vs nicotine-treated wt,
mean difference 12.89, p = 0.014, saline-treated KO vs saline-treated KO nicotine, mean differ-
ence 25.0 sec, p<0.00001). All mice were examined for tissue damage post experiments, and
no sign of tissue damage or discomfort were observed. These data suggest that that the aug-
mented antinociceptive effect of nicotine in the lynx1KO mice is mediated through nAChRs,
and that binding of lynx1 to this receptor modulates its antinociceptive properties.
Mice were tested on the hot-plate 15 minutes after injection. Nicotine-mediated antinoci-
ception is augmented in lynx1KO mice at nicotine concentrations 0.5 mgkg-1 and 1.0mgkg-1
compared to wt mice. Each data point presented as mean ± SEM. P<0.05 compared to wt
controls at corresponding concentrations of nicotine. wt: wild type, KO: lynx1 knockout. (B)
The effect of nicotine on antinociception in male and female lynx1KO mice. Antinociceptive
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Fig 3. The effect of nicotine on antinociception assessed on a hot-plate assay. (A) Antinociceptive responses in wt and lynx1KO mice after I.P. injections of
saline (n = 8 wt, 8 KO. p = 0.899, two-way ANOVA, cohen’s D 0.13) or nicotine concentrations of 0.5 mgkg-1 (n = 8 wt, 18 KO. p = 0.122, two-way ANOVA,
cohen’s D 1.36), 1.0mgkg-1 (n = 8 wt, 14 KO. p = 0.032, two-way ANOVA, cohen’s D 1.09) and 1.5mgkg-1 (8 wt, 8 KO. p = 0.657, two-way ANOVA, cohen’s D
0.13) using the hot-plate assay. ED50 was 1.05 mgkg
-1 for wt and 0.44 mgkg-1 for the lynx1KO group.
https://doi.org/10.1371/journal.pone.0199643.g003
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responses in male and female lynx1KO mice after I.P. injections of 0.5 mgkg-1 nicotine (n = 8
male, n = 8 female, p = 0.844, student’s t-test) using the hot-plate assay. Mice were tested on
the hot-plate 15 minutes after injection. There are no antinociceptive difference between sexes.
Each data point presented as mean ± SEM. (C) Antinociceptive responses in wt and lynx1KO
mice after I.P. injection of the general nAChR blocker, mecamylamine (2.5 mgkg-1) and nico-
tine (1mgkg-1) (nicotine treated lynx1KO mice (n = 14) vs. nicotine+mecamylamine treated
lynx1KO mice (n = 13): p = 0.003, Student’s T-test and nicotine treated wt mice (n = 8) vs. nic-
otine+mecamylamine treated wt mice (n = 16): p<0.001, Student’s T-test) using the hot-plate
assay. Injections of mecamylamine block the antinociceptive effect of nicotine in both geno-
types. Data indicates that lynx1 operates through nAChRs. Data presented as mean ± SEM
time. P<0.05 nicotine injected animals compared to nicotine+mecamylamine injected ani-
mals. wt: wild type (C57bl6, lynx1 +/+ and β2-GFP), KO: lynx1 knockout. We performed sta-
tistical analysis between sex, and no significant differences were seen between female and male
mice (Fig 3B).
The effects of nicotine on locomotion have been well-documented [66] and could bias the
antinociception data presented. We therefore sought to determine if changes in response time
on the hot-plate could be due to nicotine mediated changes in voluntary movements. To carry
this out, we tested locomotor activity in nicotine injected animals at the same doses used in the
hot-plate experiments. There was a dose-dependent decrease in movement in response to nic-
otine exposure (nicotine-treated wt: 0.5 mgkg-1 114.55±34.37 sec n = 7, 1.0 mgkg-1 31.46
±16.39 sec n = 6, 1.5 mgkg-1 31.09±15.43 sec n = 6 and nicotine treated lynx1KO: 0.5 mgkg-1
134.54±21.05 sec n = 8, 1.0 mgkg-1 41.13±5.81 sec n = 8, 1.5 mgkg-1 15.46±6.59 sec n = 8 in
movement from t15-t20 post drug administration), but no differences between wt and
lynx1KO mice were observed (Fig 4A). In particular, the 0.5 and 1.0 mgkg-1 dose of nicotine
(nicotine-treated wt vs. nicotine-treated lynx1KO mice: 0.5 mgkg-1 nicotine; mean difference
in movement from t15-t20 post drug administration: 19.9 sec, p = 0.56, two-way ANOVA, 1.0
mgkg-1 nicotine; mean difference in movement from t15-t20 post drug administration mean
difference: 9.7 sec, p = 0.778, two-way ANOVA), which improved antinociception in lynx1KO
mice in the hot-plate experiment (Fig 4A). In addition, in a small subgroup, we analyzed loco-
motor activity in the time period 5–10, and 15–20 minutes post injection, for saline and 0.5
mgkg-1 nicotine, to confirm that no difference in locomotor activity between genotypes was
observed at any relevant time period (Fig 4B, Figure C in S2 Fig). This is consistent with previ-
ous reports in other locomotor assays, such as the rotarod motor coordination test [48]. We
also investigated nicotine-mediated hypothermia between wt and lynx1KO mice and observed
a dose-dependent change in temperature (p = 0.00027), but no effects between genotype on
nicotine-induced drop in temperature at any of the doses tested (before injection–after injec-
tion) (nicotine-treated wt: 0.0 mgkg-1 (saline), 0.32±0.33˚, n = 11, 1.0 mgkg-1, -1.60±0.60˚,
n = 9, 2.5 mgkg-1, -3.2±0.98˚, n = 7, and nicotine-treated lynx1KO: 0.0 mgkg-1, 0.15±0.5˚,
n = 11 p = 0.79, t-test, 1.0 mgkg-1, -1.66±0.60˚,n = 11 p = 0.47 mgkg-1, 2.5 mgkg-1, -5.0
±0.61˚, n = 7, p = 0.135, t-test). (Fig 4C). Therefore, the increased latency on the hot-plate in
lynx1KO mice is likely due to a specific effect of nicotine-induced thermal antinociception
rather than nicotine metabolism, or a nonspecific effect of nicotine on systems independent of
the nociception pathway.
Since lynx1 has been shown to bind to the α4β2 nAChR subtype [44, 47], it is possible that
the modulating effect of lynx1 on nociception could be mediated through the α4β2 nAChR
subtype. Epibatidine is a non-selective α4β2 nAChR agonist [8]), which has higher affinity for
α4β2 over α7 nAChR subtypes [67–68], and preferential affinity at the low sensitivity (LS)
(α4)3(β2)2 stoichiometry of the α4β2 nAChR [69]. We tested the effect of epibatidine and
found a significant increase in time on the hot-plate in lynx1KO mice compared to wt mice
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(epibatidine-treated wt vs. epibatidine treated lynx1KO mice: mean difference 20.0 sec,
p = 0.029, Student’s T-test) (Fig 5A), suggesting that lynx1 operates through α4β2 nAChRs to
modulate their sensitivity to agonist. We tested the effect of blocking β2 nAChRs using the
selective antagonist dihydro-β-erythroidine hydrobromide (DHβE) [70]. We injected mice
with nicotine (1.0 mgkg-1) 10 minutes after DHβE (3.0mgkg-1) and tested the mice on the
hot-plate. We found that DHβE was able to significantly block nicotine’s antinociceptive effect
in lynx1KO mice, which suggests that that this effect is mediated through α4β2 nAChRs
(ANOVA, p< 0.001, F = 7.51(5,83), Tukey post-hoc test, nicotine-treated lynx1KO vs. nicotine
+DHβE treated lynx1KO mice, mean difference 26.56 secs, p = 0.001, nicotine-treated wt vs
nicotine-treated KO, mean difference 27.13 secs, p<0.001) (Fig 5B).
To confirm the interaction of lynx1 with α4β2 nAChRs, we performed co-immunoprecipi-
tation experiments using β2-GFP mice [71] to pull out native nAChR complexes from the
brain. We used anti-GFP antibodies to pull-down nAChRs and associated protein, and lynx1
as an associated part of the complex was probed using anti-lynx1 antibodies and Western blot
analyses. We could detect lynx1 present at enriched levels in the pull-down lane, whereas the
flow-through lane was blank (Figure D in S1 Fig), suggesting that lynx1 forms a stable complex
with β2-containing nAChRs. This in support of recent reports of lynx1 in aiding the assembly
and stoichiometry of α4β2 receptors [47]. In that report, there was an apparent shifting to the
low sensitivity stoichiometry of (α4)3(β2)2 by a preferential binding affinity of lynx1 to the α4:
α4 interface (Fig 5C). In order to gain insight into this idea, we employed computational
modeling to address stoichiometry-specific interactions.
We performed simulations of lynx1 binding to the interfaces of the unique interfaces of the
α4β2 receptor stoichiometries: α4:α4 vs. β2:β2. The overall architecture of lynx1 at the α4:α4
interface is shown in Fig 6.
From comparisons between α4:α4 and β2:β2 nAChRs structures in complex with lynx1, we
found that more favorable interactions exist between the α4:α4 interface and lynx1 (Fig 7). In
the α4:α4/lynx1 complex model (Fig 7A and 7C), lynx1 D55 forms three hydrogen bonds with
two residues (S170 and H169) in the α4 subunit, while two hydrogen bonds in α4 subunit are
due to substitution of E165 in the β2 subunit for S170 in the α4 subunit. Loop C of the α4
nAChR subunit closely contacts with loop I of lynx1, forming hydrogen bonds and hydropho-
bic interactions (α4 Y197 with lynx1 V6 and M18). Lynx1 R31 also interacts with nAChRs
loop C through a hydrogen bond. On the contrary, loop C of the β2 subunit (Fig 7B and 7D) is
shorter, making it difficult to generate favorable interactions with lynx1 loop I. In particular,
G154 in the α4 subunit is replaced by R149 at the equivalent position in the β2 subunit, imply-
ing that the presence of this positive charged residue could prevent lynx1 R38 from approach-
ing and interacting with Y95, W151, and Y196. In the α4:α4/lynx1 complex model, R38
appears to form hydrogen bonds with Y100 and W156, and cation-π interaction with Y204
[72]. Therefore, our modeling and simulations support the experimental results of preferential
binding affinity of lynx1 to the α4:α4 interface, as compared to the β:β interface.
More favorable interactions exist between the α4:α4 interface and lynx1; lynx1 D55 forms
three hydrogen bonds with two residues (S170 and H169) in the α4 subunit, while two
Fig 4. lynx1 does not influence nicotine-mediated locomotor performance or body temperature. (A) Effect of nicotine on locomotion
in wt and lynx1KO mice after I.P. injections of nicotine concentrations 0.5 mgkg-1 (n = 7 wt, 8 KO), 1.0mgkg-1 (n = 6 wt, 6 KO),
1.5mgkg-1 (6 wt, 6 KO). Locomotion were examined by scoring leg movements (seconds) in the time period 15–20 minutes post
injection. Injection of nicotine induce the same amount of hypolocomotion in both genotypes. Each data point presented as
mean ± SEM. wt: wild type, KO: lynx1 knockout. (B)The locomotor performance after nicotine injection (0.5 mgkg-1) was binned into 5
minute time windows and showed no significant effect of genotype at any time window. (C) Effect of nicotine on body temperature in wt
and lynx1KO mice after I.P. injections of either saline (n = 11 wt, 11 KO), or nicotine concentrations 1.0 mgkg-1 (n = 9 wt, n = 11 KO)
and 2.5 mgkg-1 (n = 7 wt, 7 KO). Each bar presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0199643.g004
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hydrogen bonds in the α4 subunit are due to substitutions of E165 in the β2 subunit for S170
in the α4 subunit. Loop C of the α4 subunit closely contacts with loop I of lynx1, forming
hydrogen bonds and hydrophobic interactions (α4 Y197 with lynx1 V6 and M18). Lynx1 R31
also interacts with loop C through a hydrogen bond. On the contrary, loop C of the β2 subunit
is shorter, making it difficult to generate favorable interactions with lynx1 loop I.
Fig 5. Mediation of lynx1 through α4β2 nAChRs. (A) Antinociceptive responses in wt and lynx1KO mice after I.P. injection of the non-selective
α4β2 nAChR agonist, epibatidine (5 μgkg-1) (n = 24 wt, 21 KO, p = 0.029, Student’s T-test). Mice were tested on the hot-plate 15 minutes after
injection. Epibatidine-mediated antinociception is augmented in lynx1KO mice compared to wt mice. Data presented as mean ± SEM time. P<0.05
compared to wt controls. wt: wild type, KO: lynx1 knockout. (B) Antinociceptive responses in wt and lynx1KO mice after I.P. injection of the α4β2
nAChRs inhibitor dihydro-β-erythroidine hydrobromide (DHβE) (3.0 mgkg-1) and nicotine (0.5 mgkg-1) (nicotine treated lynx1KO mice (n = 8) vs.
nicotine+DHβE treated lynx1KO mice (n = 6) using the hot-plate assay. Mice were injected with DHβE 25 minutes and nicotine 15 minutes prior to
hot-plate testing. Injections of DHβE blocks the antinociceptive effect of nicotine in lynx1KO mice. Data indicates that lynx1 operates through the
α4β2 nAChR to modulate antinociception. Data presented as mean ± SEM time. wt: wild type, KO: lynx1 knockout. (C) Schematic of lynx1 binding to
the LS stoichiometry of α4β2 nAChRs preferentially over the HS stoichiometry. α4β2 nAChR pentamers shown in the high sensitivity (HS) and low
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The lynx1 protein and receptor is colored yellow and green/cyan, respectively. Labels for
α4:β2 and lynx1 are colored blue and red, respectively. Potential hydrogen binding are repre-
sented as dashed red lines.
Discussion
In this study we discovered that lynx1 is expressed in at least one region of the nociception
pathway in the CNS, and that mice without the lynx1 gene demonstrated more nicotine-medi-
ated antinociception. Peak nicotine-evoked responses were larger in lynx1KO neurons in the
DRN. Furthermore, the data suggest that a possible mechanism of antinociception in the
lynx1KO is mediated through the α4β2 nAChR subtype. The data are congruent with the
hypothesis that nAChRs of lynx1KO mice are more sensitive to the effects of nicotine than
wtanimals, resulting in an improvement in cholinergic-mediated behavior; in this case
antinociception.
Serotonergic neurons in the DRN are well established components in nociception pathways
and our data demonstrate the presence of lynx1 in DRN neurons (Fig 1) [28, 73–75]. Hyper-
sensitive nAChR receptors in both serotonergic and GABAergic neurons caused by lynx1
removal could shift the excitatory-inhibitory balance towards antinociception. This does not
exclude the role of other brain regions, however, as lynx1 is widely expressed in the CNS [18].
Also, our data do not exclude a role of peripheral sites expressing nAChRs in the nociceptive
behavior. Lynx1 has not been detected in high levels in the periphery, but the effects of lynx1
outside the CNS awaits further testing. Although our data demonstrate that lynx1KO mice are
more sensitive to the effects of nicotine in the hot-plate assay than wt mice, we do not exclude
effects of endogenous acetylcholine acting in antinociception in lynx1KO mice. Since we do
not see an effect of a non-nicotinic drug (e.g ibuprofen), (Figure C in S2 Fig) the role of
Fig 6. Overall architecture of lynx1 at α4:α4 nAChR interface. Molecular dynamic simulations of lynx1 binding to
α4 nAChR subunits. The cell membrane is represented as a dashed line.
https://doi.org/10.1371/journal.pone.0199643.g006
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endogenous acetylcholine would likely be subtle, indicating another example of elevated cho-
linergic tone in these mice [18,50].
Although the precise mechanism by which lynx1 influences antinociception is as yet
unknown, lynx1 has been shown to have global and multiple effects on nAChR function [44,
47–49], so there are candidate mechanisms. The role of specific nAChRs in the DRN and noci-
ception has been demonstrated [36]. Our data are in line with reports about the involvement
of α4β2 nAChRs in antinociception [10, 11, 76–77], but does not exclude the involvement of
other nAChR subtypes [20, 23, 24, 78]. Lynx1 has also been shown to act on α5α3β4 nAChRs
[49], but an involvement at other α4β2 nAChRs (e.g., α5α4β2, α6α4β2, etc.) has yet to be
tested. In this model, we have not included the role of α7 nAChRs, which has been shown to
mediate nociceptive signaling and to bind to lynx1 proteins [22, 44]. Thus, further research
into the specific subtypes involved is needed.
Fig 7. Structural comparison between α4:α4/lynx1 and β2:β2/lynx1 complex model. (A) α4:α4/lynx1 complex model. (B) β2:β2/
lynx1 complex model (C) Structural details of boxed in A. (D) Structural details of boxed in B.
https://doi.org/10.1371/journal.pone.0199643.g007
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The biophysical mechanism of lynx1 action has been hypothesized to be due to interactions
at the interface of subunits of the nAChR pentamer. Lynx1 has also been shown to have global
allosteric actions on nAChR function. This includes, not only orthosteric effects on agonist
sensitivity, but also includes effects on desensitization kinetics, recovery from desensitization
[44, 48] and nAChR receptor closed times [49]. The antinociceptive actions of lynx1 removal
could be explained by a lynx1-directed shift in the stoichiometry of the α4β2 nAChRs from a
HS to a LS [47] (Fig 4B). The HS nAChR, adopting the (α4)2(β2)3 stoichiometry, exhibits
higher sensitivity and slower desensitization, whereas the LS nAChR, adopting the (α4)3(β2)2
stoichiometry, exhibits lower sensitivity to agonist, faster desensitization and higher Ca2+ per-
meability [69,79] In the lynx1KO mice, we expect a higher relative expression of the HS stoi-
chiometry, which is supported by our data which show an enhanced sensitivity to nicotine in
lynx1KO mice as compared to wt mice. The computer simulation data further support the HS
stoichiometry by (Figs 6 and 7) suggesting a preferential binding of lynx1 to the α4:α4 interface
of the α4β2 nAChRs. We also saw that the β2-selective nAChR antagonist DHβE was able to
block nicotine’s antinociceptive effect in lynx1KO mice, which further suggests that lynx1 is
able to modulate the α4β2 nAChR subtype, demonstrating the β2 nAChRs involvement in
antinociception but not locomotion or thermal regulation [80] (Fig 4).
Untreated acute pain can influence the development of chronic pain and can have deleteri-
ous effects on quality of life and account for billions in hospital costs [81, 82]. Thus, manage-
ment of acute pain is essential for the patient and the public health in both the short and long
term [83–84]. Our data addresses acute pain more so than chronic or neuropathic pain, but
the relationship of lynx1 to plasticity suggests that other types of pain (neuropathic, peripheral,
chronic, etc.) might be altered in our genetic model. A recent paper reported that epibatidine’s
antinociceptive efficacy declined over time in a mouse model of chronic pain and that no
changes in the number and affinity of α4β2 nAChRs occurred [85], suggesting the possibility
that lynx1 may modulate behavioral tolerance to nicotine. However, this is speculative and fur-
ther investigation is needed.
Summary: nAChRs have been implicated in nociceptive processing and has been explored
as a therapeutic avenue for the alleviation of nociception. The modulator lynx1 can regulate
nicotinic activity through its ability to bind and regulate nAChRs. We found a nicotine-medi-
ated antinociception involving α4β2 nAChRs, which is augmented in lynx1KO mice.
Supporting information
S1 Fig. Lynx1/nAChR interaction. A. Overall structures of α7/AChBP chimaera (PDB entry:
4hqp). B. Low-resolution α4:α4/lynx1 model. C. Periaqueductal grey immunostaining using
anti-lynx1 monoclonal antibody (anti-lynx1 mAb, Alexa red), 10x magnification, scale
bar = 200 μm. D. Detection of lynx1/β2 interaction by Western blot analysis after GFP co-
immunoprecipitation in β2-GFP mice. Lane 1 is the Co-IP sample. Lane 2 is the Co-IP input.
Lane 3 is a wildtype total brain homogenate (TH). Lane 4 control is an untreated total protein
homogenate from a wildtype hippocampus.
(TIF)
S2 Fig. The effect of nicotine and ibuprofen on antinociception and saline on locomotion.
A. Antinociceptive responses in wt and lynx1KO mice after I.P. injections of nicotine at con-
centrations of 0.25 mgkg-1 (n = 8 wt, 8 KO, p = 0.656 two-way ANOVA, cohen’s D 0.40), 0.5
mgkg-1 (n = 8 wt, 18 KO, p = 0.122, two-way ANOVA, cohen’s D 1.36), 1.0mgkg-1 (n = 8 wt,
14 KO, p = 0.032, two-way ANOVA, cohen’s D 1.09) and 1.5mgkg-1 (8 wt, 8 KO. p = 0.657,
two-way ANOVA, cohen’s D = 0.13) using the hot-plate assay plotted in a semi-log format.
Mice were tested on the hot-plate 15 minutes after injection. Nicotine-mediated
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antinociception is augmented in lynx1KO mice at nicotine concentrations 0.5 mgkg-1 and
1.0mgkg-1 compared to wt mice. Each data point presented as mean ± SEM. P<0.05 com-
pared to wt controls at corresponding concentrations of nicotine. wt: wild type, KO: lynx1
knockout.
B. Effect of saline on locomotion in wt and lynx1KO mice after I.P. injections of saline (n = 8
wt, n = 8 KO, not significant). Locomotion were examined by scoring leg movements (sec-
onds) in the time period 15–20 minutes post injection. The locomotor performance was
binned into 5 minute time windows and showed no significant effect at any time window.
Each data point presented as mean ± SEM. wt: wild type, KO: lynx1 knockout. C. Effect of ibu-
profen sodium salt in wt and lynx1KO mice after I.P. injection, 20 mgkg-1 (n = 10 wt, n = 12
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